AR111409A1 - SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES - Google Patents
SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINESInfo
- Publication number
- AR111409A1 AR111409A1 ARP180100849A ARP180100849A AR111409A1 AR 111409 A1 AR111409 A1 AR 111409A1 AR P180100849 A ARP180100849 A AR P180100849A AR P180100849 A ARP180100849 A AR P180100849A AR 111409 A1 AR111409 A1 AR 111409A1
- Authority
- AR
- Argentina
- Prior art keywords
- splice variant
- nucleic acid
- chemotherapeutic agents
- gene
- oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones y métodos para tratar cánceres, que comprenden administrar una combinación de agentes antineoplásicos, donde la combinación comprende agentes quimioterapéuticos de antraciclinas y una o más moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20, donde todas las variantes de empalme del gen IG20 están reguladas negativamente. En una forma de realización, la variante de empalme del gen IG20 es una variante de empalme MADD y las moléculas de ácidos nucleicos son siARN, ARNhc y oligonucleótidos antisentido que comprenden una secuencia de ácido nucleico complementaria de la secuencia de ácido nucleico del exón 13L de la variante de empalme MADD o un transcripto de ARNm del exón 13L de la variante de empalme MADD. Métodos para tratar cánceres que comprenden aplicar una terapia combinada con moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20 y agentes quimioterapéuticos de antraciclinas.Compositions and methods for treating cancers, comprising administering a combination of antineoplastic agents, wherein the combination comprises chemotherapeutic agents of anthracyclines and one or more nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene, where All splice variants of the IG20 gene are negatively regulated. In one embodiment, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, hRNA and antisense oligonucleotides comprising a nucleic acid sequence complementary to the exon 13L nucleic acid sequence of the MADD splice variant or an exon 13L mRNA transcript of the MADD splice variant. Methods for treating cancers that comprise applying a combination therapy with nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene and anthracycline chemotherapeutic agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489056P | 2017-04-24 | 2017-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111409A1 true AR111409A1 (en) | 2019-07-10 |
Family
ID=63919814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100849A AR111409A1 (en) | 2017-04-24 | 2018-04-05 | SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR111409A1 (en) |
TW (1) | TW201902912A (en) |
WO (1) | WO2018200144A2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007084954A2 (en) * | 2006-01-19 | 2007-07-26 | The Board Of Trustees Of The University Of Illinois | Selective inhibition of ig20 splice variants to treat cancers |
-
2018
- 2018-04-03 TW TW107111854A patent/TW201902912A/en unknown
- 2018-04-05 WO PCT/US2018/026173 patent/WO2018200144A2/en active Application Filing
- 2018-04-05 AR ARP180100849A patent/AR111409A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201902912A (en) | 2019-01-16 |
WO2018200144A3 (en) | 2018-11-29 |
WO2018200144A2 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017258642A8 (en) | Oligonucleotide analogues targeting human LMNA | |
CL2018000818A1 (en) | Oligonucleotide composition; methods to alter the junction of a white transcript; and use of the composition to treat duchenne muscular dystrophy. | |
CL2017001956A1 (en) | Tau antisense oligomers and their use | |
BR122021025194A8 (en) | NUCLEIC ACID MOLECULE, METHOD TO OBTAIN RNA, RNA, METHOD TO OBTAIN A PEPTIDE OR PROTEIN AND IN VITRO OR EX VIVO USES OF RNA | |
BR112017018954A2 (en) | Use of Ras Protein Mutant Form and Method to Treat Cancer | |
CO2020001354A2 (en) | Methods and compositions for treating a bleeding event in a subject suffering from hemophilia an RNA, for example, a double-stranded ribonucleic acid (rnhd), compositions targeting the serinc1 gene, and methods for using said RNA, for example, rnhd, compositions for treat a bleeding event in a subject who has hemophilia (eg, with or without inhibitors). | |
WO2013086444A3 (en) | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna | |
PE20171763A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE HAO1 GENE (HYDROXIACIDE-OXIDASE 1 (GLYCOLATE-OXIDASE)) | |
AR090641A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1 | |
PE20181448A1 (en) | COMPOSITIONS AND METHODS TO REDUCE THE EXPRESSION OF TAU | |
CL2020002563A1 (en) | Use of fubp1 inhibitors for the treatment of hepatitis b virus infection | |
CL2021001552A1 (en) | Inhibitory double-stranded nucleic acid molecules containing a triloop | |
EA201791986A1 (en) | Oligonucleotides, corresponding to exon 73 of the COL7A1 gene, for the therapy of bulletic epidermolysis | |
BR112017018329A2 (en) | DPP-4 prevention or treatment composition for the calcification of the valve containing the inhibitor | |
CL2021002842A1 (en) | Inhibitory double-stranded nucleic acid molecules with shortened sense strands | |
AR120341A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE | |
AR111409A1 (en) | SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES | |
MX2022009870A (en) | Rnas for complement inhibition. | |
AR111587A1 (en) | SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND RENTING CHEMOTHERAPEUTIC AGENTS | |
AR111410A1 (en) | SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES | |
MX2017014855A (en) | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa. | |
WO2016107933A3 (en) | Materials and methods for the treatment of cancers | |
CO2020010226A2 (en) | Oligonucleotide therapy for wilson's disease | |
AR111449A1 (en) | SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPY WITH TAXANOS | |
AR125447A2 (en) | SERPINA1 RNAi COMPOSITIONS AND THEIR METHODS OF USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |